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Chronic liver disease (CLD) is frequently seen in the hemophilia population. The ADVANCE Working Group conducted a cross-
sectional study in which people with hemophilia (PWH) aged ≥40 years were included. This study aimed to assess the associations
between CLD and its risk factors using data from the H3 study, and to suggest implications for optimal care.
Data from 13 European countries were collected at a single time-point (2011–2013). Univariate and multivariate logistic regression
(MLR) analyses were performed.
A total of 532 PWH were included with either hemophilia A (n=467) or hemophilia B (n=65). A total of 127 (24%) were diagnosed
with CLD. Hepatitis C virus (HCV), human immunodeficiency virus (HIV), total cholesterol, and severe hemophilia were significant risk
factors in univariate logistic regressions. In MLR, HCV Ab+/PCR+ (OR=17.6, P< .001), diabetes (OR=3.0, P= .02), and HIV (OR=
1.9, P= .049) were positively associated with CLD. Total cholesterol (OR=0.6, P= .002) was negatively associated with CLD. We
found no evidence of interaction effects among the explanatory variables. No significant associations with age and type of or severity
of hemophilia were observed in MLR.
The main risk factors for CLD in this European cohort also apply to the general population, but the prevalence of HCV and HIV is
considerably larger in this cohort. With new and improved treatment options, intensified eradication therapy for HCV seems justified
to prevent CLD. Similarly, intensified monitoring and treatment of diabetes seem warranted.
Abbreviations: BMI= bodymass index, CLD= chronic liver disease, CRF= case report form, DAA= direct-acting antiviral, ESLD
= end-stage liver disease, HAART = highly active antiretroviral therapy, HBV = hepatitis B virus, HCC = hepatocellular carcinoma,
HCV = hepatitis C virus, HIV = human immunodeficiency virus, IR = insulin resistance, MLR =multivariate logistic regression, NRTI =
nucleotide reverse transcriptase inhibitor, PWH = people with hemophilia, SVR = sustained virologic response, T2D = type 2
diabetes.
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Chronic liver disease (CLD) is recognized as a major cause of
morbidity and mortality in people with hemophilia (PWH). Prior
to the mid-1980s, factor concentrates contaminated with
hepatitis C virus (HCV) were used for the treatment of PWH,
resulting in mass infection and death of PWH worldwide, and
many were coinfected with human immunodeficiency virus
(HIV).[1,2] Except from viruses of contaminated transfusions,
PWH are not known to have greater exposure to other risk
factors for CLD than the general population.[3]
HCV infection is amajor cause of cirrhosis, progression to end-
stage liver disease (ESLD), hepatocellular carcinoma (HCC), and
liver-related death in the Western world.[4] As a slowly
progressive disease, cirrhosis develops in approximately 10%
to 20% of patients over the course of 20 to 30 years. With
cirrhosis established, the estimated annual risk of HCC is 1% to
5%, of hepatic decompensation 3% to 6%, and following an
episode of decompensation, the risk of death in the following
years is 15% to 20%. Studies of PWH have shown that HIV-
HCV coinfection leads to accelerated HCV infection, and in 10%
to 35% of the cases, ultimately ESLD.[5–10] Longer duration of
HCV infection, alcohol abuse, HIV coinfection, older age at
infection, and presence of HCV genotype 1 have been identified
[8]
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of highly active antiretroviral therapy (HAART) in the mid-
1990s has diminished the mortality due to HIV-AIDS (acquired
immunodeficiency syndrome). For individuals with HCV, and in
particular those with HIV-HCV coinfection, CLD is the leading
cause of morbidity and mortality.[11–15]
The ADVANCE (age-related-developments-and-comorbid-
ities-in-hemophilia) Working Group conducted an epidemiologi-
cal study of hematuria and hypertension in hemophilia A and B
(the H3 study), a multicenter, observational, noninterventional
cross-sectional design.[16]
Using data from theH3 study, we have assessed the associations
between CLD and clinically interesting risk factors and examined
whether this European cohort differs from the general population
and previous studies of PWH. The papers by Goedert et al and
Posthouwer et al[7,8] are similar to ours but differ in some
important respects. They have assessed the risk factors for
developing ESLD using survival analysis, whereas we have studied
risk factors for any type of CLD and disease progression using
logistic regressions. Another difference is that they have considered
only patients with HCV whereas our cohort included noninfected
patients. Based on our findings and recent advances in treatment
options, we have suggested implications for optimal care.
2. Methods
2.1. Data collection
The dataset, consisting of 532 patients aged 40 years and older,
was collected between June 2011 and September 2013 from
researchers in 16 participating centers in 13 European countries,
where Germany had 3 centers and Italy had 2.[16] All data were
gathered from consecutive PWH attending their routine clinical
visit using a case report form (CRF) and from laboratory data
collected no earlier than 1 year prior to the clinical visit. The CRF
included items about patient characteristics, demographics, past
and current treatment, and medical history including a lifetime
history of comorbidities. Consenting patients with all severities of
hemophilia A or B were included in the study and only patients
below 40 years of age were excluded. In the CRF, the physician
recorded the binary variable CLD as either present or absent.
CLD, if present, was diagnosed as fibrosis or cirrhosis withTable 1
















The patients column reports the number of patients by country. Columns CLD through DIAB report the fracti
diabetes, respectively. The final column reports average total cholesterol (not recorded in Sweden). CHOL=
immunodeficiency virus.
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ultrasound, transient elastography, biopsy, or as evidenced by
portal hypertension/variceal disease. In addition, persisting (>6
months) abnormal/elevated liver transaminases qualified as
chronic hepatitis. The presence or absence of HCV antibody
and HCV RNA was used for the diagnosis of HCV infection and
further categorized into 4 groups: HCV Ab positive PCR positive
(Ab+/PCR+), HCV Ab negative PCR negative, patients with
persistent response to antiretroviral drugs, and patients with
natural clearance of HCV. Antibodies toHIVwere determined by
serological testing and reported in the CRF as existent or not. If
applicable, HIVwas reported together with the variable HAART.
Diabetes was recorded as present if a patient had a known
diagnosis or if currently on medication for diabetes. The study
was approved by respective national ethical committees or the
institutional review boards.2.2. Statistical analysis
We have performed univariate and multivariate logistic regression
(MLR) analyses to ascertain associations betweenCLDand its risk
factors. Statistical analysis was performedwithR version 3.5.0.[17]
Throughout we have used a two-sided .05 significance level.3. Results
3.1. Patient characteristics
A total of 98% of patients were Caucasian with median age 52
years (range 40–98 years). Each patient was characterized by type
and severity of hemophilia: 467 (87.8%) hemophilia A, 65
(12.2%) hemophilia B, and 59% with severe, 11% with
moderate, and 30% with mild hemophilia.3.2. Descriptive results
There were 127 (24%) patients with CLD, 397 without, and 8
with missing CLD data. A total of 216 (42%) patients were HCV
Ab positive PCR positive (Ab+/PCR+), 30% were HCV Ab
negative PCR negative, 18% had persistent response to
antiretroviral drugs, and 11% were reported with natural
clearance of HCV. HIV infection was present in 106 (20%),
97% of whomwere treated with HAART. HIV-HCV coinfectionHCV HIV DIAB CHOL
0.75 0.20 0.05 4.72
0.33 0.28 0.08 4.90
0.43 0.13 0.13 4.48
0.40 0.40 0.20 4.74
0.55 0.27 0.18 4.59
0.42 0.19 0.13 4.91
0.36 0.11 0.09 4.65
0.33 0.05 0.15 4.79
0.68 0.00 0.10 3.87
0.42 0.05 0.05 4.44
0.48 0.42 0.13 4.26
0.48 0.18 0.05 NA
0.40 0.27 0.07 4.79
0.42 0.20 0.10 4.71
on of patients with the condition, that is, having CLD, HCV equal to Ab+/PCR+, HIV positive, and having
total cholesterol, CLD= chronic liver disease, DIAB=diabetes, HCV=hepatitis C virus, HIV=human
Table 2
Descriptive statistics by age group.
Age group Patients CLD HCV HIV DIAB CHOL
40–49 y 222 0.24 0.43 0.32 0.04 4.79
50–59 y 152 0.22 0.41 0.16 0.07 4.69
60–69 y 89 0.30 0.48 0.10 0.15 4.66
70–79 y 56 0.20 0.31 0.05 0.27 4.55
80–100 y 13 0.31 0.46 0.00 0.46 4.44
Total 532 0.24 0.42 0.20 0.10 4.71
The patients column reports the number of patients by age group. Columns CLD through DIAB report the fraction of patients with the condition, that is, having CLD, HCV equal to Ab+/PCR+, HIV positive, and




Variable Level Reference level OR 95% CI P-value n
HCV Ab+/PCR+ Not Ab+/PCR+ 22.73 (12.88, 43.03) <.001 520
HAART Yes No 2.26 (1.42, 3.58) <.001 524
HIV Positive Negative 2.18 (1.37, 3.44) <.001 523
Alcohol/week 1–5 units 0 units 0.46 (0.29, 0.71) <.001 509
Total cholesterol 0.45 (0.35, 0.57) <.001 444
Haemophilia severity Severe Mild 2.05 (1.28, 3.4) .004 523
Employment status Early retirement Full-time 2.01 (1.02, 3.87) .04 519
Diabetes Yes No 1.60 (0.84, 2.93) .14 520
This table reports separate univariate logistic regressions with CLD as the response and the variables in the first column as covariates. The 2nd column lists the level which generated a significant coefficient for the
categorical variables. The 3rd column lists the corresponding reference level. Each OR in the table is accompanied by a 95% confidence interval and the corresponding 2-sided P-value. The final column reports
the number of observations used when estimating the model. Diabetes is included in the table for reference and comparison with the MLR, in which it became significant. CLD=chronic liver disease,
CI= confidence interval, HAART=highly active antiretroviral therapy, HCV=hepatitis C virus, HIV=human immunodeficiency virus, OR= odds ratio.
Qvigstad et al. Medicine (2018) 97:39 www.md-journal.comwas present in 89 patients (17%). A total of 52 (10%) of the
patients were diagnosed with diabetes. Themedian value for total
cholesterol was 4.63mmol/L (range 2.15–8.32mmol/L).
The highest prevalence of CLD was found in patients
recruited from Spain (Table 1). There were no patients with
CLD in either Austria or Norway. We attribute this to
randomness, as there was no deliberate strategy in place for
avoiding CLD patients. Diabetes ranged from 5% to 20% for
the countries in this sample.
The number of recruited patients decreased by age group
(Table 2), with most patients in the range 40 to 49 years. HIVwas
most prevalent in this age group (32%). In the age group 70 to 79
years, 31% had HCV, which was lower than the other groups
that ranged between 41% and 48%. Prevalence of diabetes
increased with age, from 4% in the 40 to 49 to 46% in the 80 to
100 years age group.Table 4
Prevalence of risk factors and CLD status.
CLD HCV HIV
A. Prevalence of risk factors by CLD status
No 0.26 (103/393) 0.17 (67/396)
Yes 0.89 (113/127) 0.31 (39/127)
All 0.42 (216/520) 0.20 (106/523
B. CLD status by presence of risk factors
No 0.05 (14/304) 0.21 (88/417)
Yes 0.52 (113/216) 0.37 (39/106)
All 0.24 (127/520) 0.24 (127/523
Panel A reports the fraction of patients with the condition specified in the header grouped by CLD status. T
status. The denominator is the number of patients with valid observations for the corresponding CLD status
reports the fraction of patients without and with CLD conditional on the presence of the risk factor specified
of the specified risk factor. The denominator is the number of patients with valid observations for the risk fa
column correspond to the fraction of patients in the <33rd percentile. CHOL= total cholesterol, CLD= c
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3.3. Univariate associations
In univariate logistic regressions, we found significant associ-
ations with P< .01 between CLD and severity of hemophilia,
HIV, HAART, HCV, total cholesterol, and alcohol (Table 3). In
unreported results, we found that the coefficient estimates for
the HCV levels natural clearance and persistent response to
antiviral drugs were statistically indistinguishable from the
reference level, Ab negative/PCR negative. Hence, in Table 3
and the remainder, we have recoded HCV to a binary variable
with HCV diagnosed as Ab+/PCR+ or not. One further
significant association with P< .05 was found with employment
status. No significant associations were found with age,
diabetes, malignancy, time on current treatment regimen, body
mass index (BMI), weight, NSAID use, hypertension, or
smoking status.DIAB CHOL
0.09 (35/394) 0.26 (89/342)
0.13 (17/126) 0.52 (53/102)
) 0.10 (52/520) 0.32 (142/444)
0.23 (109/468) 0.16 (49/302)
0.33 (17/52) 0.37 (53/142)
) 0.24 (126/520) 0.23 (102/444)
he numerator in the parentheses shows the number of patients with the condition for a particular CLD
. The number in the denominator is not constant across risk factors because of missing data. Panel B
in the header. The numerator shows the number of patients with the specified CLD status and presence
ctor in question. The final row in each panel shows the results for all patients. The numbers in the final
hronic liver disease, DIAB=diabetes, HCV=hepatitis C virus, HIV=human immunodeficiency virus.
Table 5
Multivariate logistic regression.
Variable Odds ratio 95% CI P-value
HCV Ab+/PCR+ 17.57 (9.15, 36.65) <.001
Total cholesterol 0.62 (0.46, 0.84) .002
HIV 1.86 (1, 3.44) .049
Diabetes 2.96 (1.19, 7.5) .02
This table shows the results from a multivariate logistic regression with CLD as the response and the
variables in the first column as covariates. Each odds ratio in the table is accompanied by a 95%
confidence interval and the corresponding 2-sided P-value. The sample size is 437. The main reason
for reduced sample size is due to some missing data for total cholesterol. CI= confidence interval,
HCV=hepatitis C virus, HIV=human immunodeficiency virus.
Table 7
Ordinal logistic regression with continuation ratio model.
Variable Odds ratio 95% CI P-value
HCV Ab+/PCR+ 15.75 (7.53, 32.95) <.001
Total cholesterol 0.58 (0.43, 0.77) <.001
HIV 1.97 (1.17, 3.33) .011
Diabetes 2.57 (1.2, 5.49) .015
This table shows the results from a continuation ratio logistic model. The model has been constrained
to have a common vector of slope coefficients. Each odds ratio in the table is accompanied by a 95%
confidence interval and the corresponding 2-sided P-value. The sample size is 418. The reason for
reduced sample size compared to the multivariate logistic regression is that some patients have been
diagnosed with an unspecified chronic liver disease. CI= confidence interval, HCV=hepatitis C virus,
HIV=human immunodeficiency virus.
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status. The percentages of patients with HCV Ab+/PCR+,
diabetes, HIV, and lowest 3rd of total cholesterol were higher
for patients with CLD than for those without. For example, when
CLD is present 89% are HCV Ab+/PCR+ whereas only 26% are
Ab+/PCR+ otherwise. Panel B shows that CLD increases with the
presence of risk factors. In patients with HCV Ab+/PCR+, 52%
are reported to have CLD and 5% not. The 33rd percentile,
corresponding to 4.1mmol/L, is a somewhat arbitrary cut-off
value but serves to illustrate the strong association between low
total cholesterol levels and CLD. In the logistic regressions, we
have used the continuous variable total cholesterol as recorded in
the dataset.3.4. Multivariate associations
In MLR, we have assessed the associations between CLD and the
covariates HCV, total cholesterol, HIV, and diabetes (Table 5).
HCV Ab+/PCR+ was positively associated with CLD (OR=
17.57 [9.15, 36.65], P< .001). Diabetes was not significant in
univariate logistic regression, but after controlling for HCV the
coefficient estimate increased, revealing a positive association
with CLD (OR=2.96 [1.19, 7.5], P= .02). The interaction term
for HCV and diabetes was insignificant implying that HCVwas a
confounder but not an effect modifier for diabetes. Total
cholesterol was negatively associated with CLD with OR=
0.62 (0.46, 0.84), P= .002 for each 1.0mmol/L increment. HIV
was associated with an increased likelihood of CLD (OR=1.86
[1, 3.44], P= .049). We found no evidence of interaction effects
among the explanatory variables.
Several measures of goodness of fit for a logistic regression
model exist. The widely recommended le Cessie–van Houwelin-
gen–Copas–Hosmer unweighted sum of squares test[18] gave a P-
value of .9, and hence we could not reject the null hypothesis that
the model fitted. The Hosmer–Lemeshow test yielded the same
conclusion.Table 6
Distribution of chronic liver disease type.
Liver status Number of patients Frequency
No CLD 397 76
Cirrhosis 46 9
Fibrosis 41 8
Not specified 28 5
Steatosis/hepatitis 12 2
Total 524 100
This table shows the breakdown of patients by CLD type. The sum total of 524 is slightly less than the
total number of patients due to some missing data points on CLD. CLD= chronic liver disease.
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3.5. Risk factors across type of CLD
We have mapped the reported CLD type to 3 major categories:
cirrhosis, fibrosis, and steatosis/hepatitis (Table 6). Patients with
an unspecified CLD were disregarded. CLD can deteriorate
according to no CLD≺ steatosis/hepatitis≺fibrosis≺cirrhosis,
where ≺ indicates that the condition on the right is more severe
than that on the left side of the sign. Since a patient must pass
through the previous stages of the disease in order to reach a
certain level, we have used a continuation ratio ordinal model
taking the rank ordering of the CLD type into account. This
model assesses the probability of proceeding to the next stage of
CLD, conditional on not having reached that stage yet, and the
set of risk factors. We found all risk factors included in Table 5
statistically significant at the 5% level (Table 7). This model
implies that at each stage of the disease, HCV, HIV, and diabetes
increase the risk of the condition deteriorating. The results were
consistent with and provided additional credence to the MLR in
Table 5. The odds of proceeding from, for example, chronic
hepatitis to fibrosis, or from fibrosis to cirrhosis are 15.75 times
higher for a patient withHCVAb+/PCR+. HIV and diabetes have
odds ratios 1.97 and 2.57, respectively. When total cholesterol
increases by 1 unit, the odds are reduced by a factor of 0.58. A
likelihood ratio test showed that we could not reject that the
model parameters were constant across CLD type.
4. Discussion
4.1. HCV
As expected, MLR demonstrated that HCV Ab+/PCR+ was
positively associated with CLD. The majority (89%) with CLD in
this cohort was HCV Ab+/PCR+, presumably due to the difficult
management of HCV in PWH, as previous interferon-based
treatments had limited efficacy and were poorly tolerated.
However, since their introduction in 2011, treating HCV-
infected with direct-acting antivirals (DAAs) offer high cure rates.
Sustained virologic response (SVR) of more than 95% of the
patients within 12 to 24 weeks of treatment has been reported in
several papers, and similarly in patients with previous treatment
failure, for coinfected patients, and also not limited by HCV
genotype.[19,20] One of the main findings from the ongoing
prospective Swiss HIV Cohort Study[21] was that treated patients
with non-SVR compared to those with SVR had a higher risk of
liver events, liver-related death, and diabetes. A significant
decrease of liver-related disease and death, as well as a reduction
of diabetes, was observed following viral eradication. In a recent
study,[22] 120 patients with bleeding disorders (91% hemophilia)
andHCVwere treated with DAAs. SVRwas achieved in 99% for
the most common HCV genotypes after 12 weeks of treatment,
Qvigstad et al. Medicine (2018) 97:39 www.md-journal.comand the authors concluded that patients with bleeding disorders
could receive successful treatment for HCV infection with DAA
regimens without significant safety concerns.
As chronic HCV infection is a slowly progressive disease, and
most PWH have had long-term exposure, early and intensified
eradication therapy with DAAs seems justified to prevent CLD.4.2. Diabetes
After controlling for HCV in MLR, we found diabetes positively
associated with CLD. The mechanisms through which HCV
induces type 2 diabetes (T2D) include direct viral effects, insulin
resistance (IR), pro-inflammatory cytokines, and other immune-
mediated processes.[23] Numerous studies indicate that HCV-
associated IR/T2D leads to an increased risk of fibrosis
progression,[24,25] and having T2D is associated with the
progression of chronic HCV infection, decreased response to
HCV treatment, and increased risk of HCC. A meta-analysis
examining the relationship between HCV infection and risk of
T2D[26] demonstrated a 2-fold significant increase in the risk of
T2D with HCV infection, and a large population-based study[27]
found that T2D and IR were independently associated with liver-
related mortality in HCV-infected persons.
Diabetes is associated with increased risk of complications and
mortality rates in patients with CLD. It enhances inflammation
and fibrosis of the liver, and treatment has been difficult due to
impaired hepatic function and drug toxicity. Now, new and safe
treatment options exist with dipeptidyl peptidase-4 inhibitors
that are only minimally metabolized in the liver and are excreted
unchanged by the kidney.[28] Consequently, intensified monitor-
ing and treatment of T2D seems warranted in PWH. It is
particularly important to screen for non-alcoholic steatohepatitis
in patients with T2D and additional risk factors such as
dyslipidemia and obesity, especially in non-European popula-
tions where the prevalence is increasing significantly. Further-
more, curing HCV may result in a reduced incidence of T2D and
HCV-infected diabetics may improve diabetes-related clinical
outcomes if SVR is achieved.[29]4.3. Cholesterol
Total cholesterol was negatively associated with CLD in both
univariate andMLR. It is recognized that HCV infection results in
lower cholesterol levels, and also that cholesterol levels inHCVAb
+/PCR+ subjects are significantly lower than in subjects who are
HCVAb+ but PCRnegative.[30] There is a strong relation between
lipid metabolism and HCV infection, with circulating virus being
bound to lipoproteins in serum, and the HCV life cycle being
dependent on lipids from entry to hepatocytes to viral replica-
tion.[31–33] In a study of more than 700 PWH,[34] total cholesterol
levels were significantly lower in PWH than in the general
population andmean total cholesterol levels were lower in patients
with active chronic HCV infection than in patients without.
In our data, HCV is a categorical variable that gives no
additional information about the severity of the infection. The
mean mmol/L of total cholesterol decreases monotonically by
severity of CLD, from no evidence of CLD (4.90), to steatosis/
hepatitis (4.44), to fibrosis (4.10), and finally to cirrhosis (3.78). It
is our conjecture that total cholesterol adds information about the
degree ofHCV infection, for example, anHCVAb+/PCR+ patient
with low total cholesterol is likely to have a serious infection.
Therefore, total cholesterol in combination with HCV is an
important risk factor that should be included in the model and5
statistical tests confirmed that the model improved significantly by
including total cholesterol. Nevertheless, we are aware that CLD
may also yield lower cholesterol levels and we acknowledge that
there may be instances of reverse causality as well. Omitting the 61
patients that used statins, only 13 of them HCV Ab+/PCR+, the
significance of HIV is at the 10% level whereas the other risk
factors, and especially total cholesterol, increase their significance.
Our opinion is that intensified antiviral treatment seems needed for
HCV-infected patients with low cholesterol.4.4. HIV/HAART
HIV was significantly associated with an increased likelihood of
CLD. This association has been recognized by other groups,[35,36]
and also the potential of antiretroviral drugs to cause
hepatotoxicity, as longer exposure to HAART has been
associated with an increased mortality from liver-related disease.
From the D:A:D study of HIV-positive andmainly HCV-negative
people, the authors identified cumulative use of nucleotide reverse
transcriptase inhibitors (NRTIs) to be independently associated
with an increased rate of ESLD/HCC development. There was
also limited evidence for reversibility of ESLD/HCC risk upon
cessation of NRTIs.[37]
It has been debated whether HIV infection itself, the use of
HAART, or immunodeficiency is the cause of CLD. The results in
Table 5 are robust to replacing HIV with HAART, as all risk
factors remain significant at the 5% level, and even with a slightly
lower P-value for HAART than HIV. In either case, age-related
effects of the liver in HIV-infected people, HCV-coinfection, and
the toxicity of long-termHAART are of concern. Even though the
use of NRTIs is reduced in modern HIV treatment, we might see
more CLD due to NRTIs in the ageing HIV population.4.5. Significant univariate associations not considered risk
factors in this cohort
A considerable number of patients (39%) were abstinent from
alcohol, and it seems reasonable to assume that several refrain
from drinking because of CLD. Alcohol was therefore omitted as
an explanatory variable in theMLR. Employment status reported
as early retirement, approximately 82% in the age range 40 to 59
years, was significant in univariate logistic regression but became
insignificant in the MLR. This could be due to early retirement
being attributable to deteriorating health, captured by controlling
for HCV, HIV, and diabetes. Severe hemophilia was also
significant in univariate logistic regression, but insignificant after
controlling for HCV in MLR. This is likely due to those with
severe hemophilia receiving more transfusions, thus increasing
the probability of a transfusion contaminated with HCV. The
data confirm that HCV prevalence increases with severity of
hemophilia. Beta blockers were significantly associated with
increased likelihood of CLD, but they are often included in the
treatment of patients already suffering from cirrhosis and
consequently omitted from our model. Modification of diet in
renal disease was statistically significant, but not included due to
reverse causation as renal failure is known to be a common and
severe complication of progressive cirrhosis.4.6. Risk factors recognized in the literature but absent for
this cohort
The set of risk factors we have identified for this European cohort
is not exhaustive. Previous research has identified additional risk
Qvigstad et al. Medicine (2018) 97:39 Medicinefactors, including, but not limited to excessive alcohol consump-
tion, older age, and metabolic syndromes related to overweight
and obesity, hypertension, hyperglycaemia, and dyslipidemia.
Posthouwer et al found that excessive alcohol consumption was
a significant risk factor. Compared to abstinence, we found a
significant risk-reducing effect from moderate alcohol consump-
tion (1–5units/week) and a risk-increasing but not significant
adverse effect from heavy drinking (>20units/week), a result we
attribute to reverse causality.We foundnoevidence that ageplayed
a role in the development or progression of CLD, in contrast to
Goedert et al and Posthouwer et al. Our cohort consisted of only
adult PWH, whereas their cohorts included children as well as
adults. Even though development of CLD is time dependent, this
could suggest that there exists a threshold after which time since
infection is no longer of significance as few, if any, were infected
after the early 1990s.We did not find an association betweenCLD
and BMI, although both mean and median BMI were >25 in this
sample. A likely reason is that CLDwas not frommetabolic origin
in this cohort but rather from HCV infection (89%). Apart from
total cholesterol and T2D, further blood biochemical parameters
and anthropometric measurements were not associated with CLD
in this cohort of PWH.4.7. Noninvasive assessment of liver fibrosis
Recent advances in pharmaceutical therapies have significantly
improved life expectancy in PWH with HCV-related CLD, and
non-invasive monitoring of disease progression has reduced the
bleeding risk from biopsy. Although liver biopsy has been the
gold standard for identifying and evaluating liver fibrosis, it is not
required before starting antiviral treatment. Also, the need for
factor concentrates and hospitalization due to the bleeding risk in
PWH undergoing biopsy has been a significant disadvantage.
However, transient elastography is a painless and quick
procedure that can easily be performed in the outpatient clinic.
As reviewed by Coppola et al,[38] several studies have recognized
this noninvasive technique as a reliable alternative to liver biopsy.
The need for biopsies in PWH has been greatly reduced as this
method offers an accurate staging of fibrosis. In addition, good
reproducibility and accessible repeated procedures have provid-
ed a risk-free method to monitor disease progression of fibrosis
and cirrhosis, and it serves as both a diagnostic and prognostic
tool.4.8. Limitations
A cross-sectional study means that it is difficult to statistically
differentiate between causes and consequences of CLD. Howev-
er, theory and previous studies guide our hypotheses regarding
causality. Another limitation was that most data were collected
retrospectively. In our data, 21/46 (46%) of patients with
cirrhosis were classified by Child–Pugh score (mainly class A),
some patients were classified by MELD-score (Model for ESLD),
and even more were classified by transient elastography for both
fibrosis and cirrhosis. However, it is a limitation that some
patients were only reported with either fibrosis or cirrhosis
without any further information by what method they were
classified. The specific field in the CRF for reporting on current
CLD status and staging was text based, and only 1 patient was
described as being evaluated for a liver transplant. A further
limitation was the lack of data for hepatitis B virus (HBV). Even
though HCV usually dominates and suppresses HBV replica-
tion,[39] we cannot dismiss an additional role of HBV in CLD.6
Missing data caused the removal of some patients in the MLR.
Despite these limitations, the H3 study[16] represents a
comprehensive multicountry hemophilia sample which adds to
the generalizability of the results.5. Conclusion
We have confirmed previous research findings, both for PWH
and the general population, that HCV and HIV coinfection/
treatment are significant risk factors for CLD in this new dataset
on PWH comprising several additional European countries. In
addition, we found that diabetes and low levels of total
cholesterol were further significant associated factors in
multivariate analysis. In contrast to the general population, we
usually know both status and time ofHCV infection in PWH, and
long before the development of CLD. The majority who
contracted HCV in this cohort did so in the 1980s, and it may
take 30 years to reach the final stages of CLD. Therefore, the
prevalence and severity of CLD may not have reached its peak
yet. Using an ordinal model, we have shown that the same set of
risk factors is responsible for the deterioration of CLD, implying
that treatment at any stage of the disease is paramount. With
well-organized and swift implementation of treatment, the
concept of microelimination is to completely eliminate HCV
infection in targeted populations such as PWH. This is on-going
in some countries, still all PWH certainly need to be allowed this
therapy. Hence, intensified eradication therapy for HCV with
DAAs seems justified to prevent the potentially fatal consequen-
ces of advanced CLD.
In addition, intensified monitoring and treatment of T2D
appears warranted. This is particularly true in the new treatment
era with dipeptidyl peptidase-4 inhibitors, considered safe to use
in the treatment of diabetes in patients with CLD.
The ADVANCE group is currently conducting a prospective,
longitudinal study that will offer the opportunity to study the
causal relationships of CLD in PWH in more detail.Acknowledgments
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